# Veradermics to Present Phase 3 Hair Loss Trial Results

- URL: https://stocks.freetheai.org/news/veradermics-to-present-phase-3-hair-loss-trial-results-16ae16
- Published: 2026-10-18T22:00:00Z
- Category: company_news; sentiment: neutral; impact: high
- Symbols: [NYSE:MANE](https://stocks.freetheai.org/symbols/NYSE-MANE)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Veradermics, Incorporated (NYSE:MANE) will hold an investor call and live webcast on October 19, 2026, at 8:00 a.m. ET to present initial Phase 3 results for its lead drug candidate, VDPHL01. The Study '304' trial evaluated the extended-release oral minoxidil tablet in 536 men with mild-to-moderate pattern hair loss over a randomized, double-blind, placebo-controlled study period.

The trial outcome represents a key milestone for the biopharmaceutical firm, which is developing non-hormonal oral treatments for hair restoration. Pattern hair loss impacts roughly 80 million individuals in the United States, and no new prescription treatments have received regulatory approval in nearly three decades. If approved, VDPHL01 could become the first oral non-hormonal treatment for male and female pattern hair loss.

Investors and clinical observers will evaluate the co-primary endpoint data from Month 6 during the upcoming conference call. The broader clinical program includes two additional Phase 2/3 trials across more than 1,600 total subjects, aiming to support potential regulatory submission to the U.S. Food and Drug Administration. Ahead of the presentation, company shares traded down 5.43% to $108.80.

## Key points

- Veradermics scheduled an investor call for October 19, 2026, to discuss Phase 3 trial results for VDPHL01.
- Study '304' evaluated the proprietary extended-release oral minoxidil tablet in 536 male patients.
- VDPHL01 aims to become the first non-hormonal oral treatment approved for pattern hair loss in almost 30 years.
- Shares of Veradermics (NYSE:MANE) traded down 5.43% to $108.80 ahead of the data release.

## Questions and answers

### When will Veradermics present its Phase 3 trial results?

Veradermics will present results from its Phase 3 Study '304' trial on Monday, October 19, 2026, at 8:00 a.m. ET via investor call and live webcast.

### What is VDPHL01 and how does it work?

VDPHL01 is an investigational extended-release oral minoxidil formulation designed to provide steady absorption and avoid high peak drug concentrations while promoting hair growth in men and women.

### How many patients participated in the Study '304' trial?

Study '304' evaluated 536 male participants with mild-to-moderate pattern hair loss in a randomized, double-blind, placebo-controlled study.